Your browser doesn't support javascript.
loading
Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
Wu, Bin; Gu, Xiaohua; Zhang, Qiang.
Affiliation
  • Wu B; Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China. Electronic address: scilwsjtu-wb@yahoo.com.
  • Gu X; Department of Respiratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China.
  • Zhang Q; Department of Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
J Thorac Oncol ; 13(2): 184-193, 2018 02.
Article in En | MEDLINE | ID: mdl-29101057
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Cost-Benefit Analysis / Antineoplastic Agents Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: J Thorac Oncol Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Cost-Benefit Analysis / Antineoplastic Agents Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: J Thorac Oncol Year: 2018 Document type: Article Country of publication: United States